Using machine learning to identify patients with cancer that would benefit from immunotherapy
A new study examines the development of two machine learning models to classify the immunophenotype of a cancer specimen.
Apr 16, 2024
0
0
A new study examines the development of two machine learning models to classify the immunophenotype of a cancer specimen.
Apr 16, 2024
0
0
Catherine Wu has been a pioneer in a promising approach to fight cancer: vaccines that target specific immune-stimulating molecules, known as immunogenic peptides, generated by the distinct genetic mutations of any individual ...
Apr 16, 2024
0
0
Mailed at-home self-sampling for human papillomavirus (HPV) testing increases cervical cancer screening participation in underscreened populations by almost threefold, according to a study presented at the annual meeting ...
Apr 13, 2024
0
0
A research team from the National University of Singapore (NUS) has unearthed new findings that may help explain the connection between cancer risk and poor diet, as well as common diseases like diabetes, which arise from ...
Apr 12, 2024
1
97
As part of a comprehensive effort to improve cancer screenings among diverse communities, Penn Medicine's Abramson Cancer Center (ACC) Community Outreach and Engagement team developed a culturally sensitive educational video ...
Apr 9, 2024
0
0
For patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, cadonilimab plus chemotherapy is associated with improved overall survival and progression-free survival, according to a study presented at the annual ...
Apr 8, 2024
0
0
A blood test appears capable of detecting early-stage pancreatic cancers with up to 97% accuracy, a new study reports.
Apr 8, 2024
0
1
The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free survival and overall survival in patients with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal ...
Apr 8, 2024
0
0
SYNC-T, an investigational therapy that combines a device-induced vaccination at the tumor site with intratumoral infusion of a multitarget biologic drug led to numerous clinical responses in patients with metastatic castrate-resistant ...
Apr 8, 2024
0
0
The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable safety profile in patients with homologous recombination repair (HRR)-deficient breast cancers, according to results ...
Apr 8, 2024
0
0